Cipla and Kemwell to form joint venture targeting respiratory biosimilars market

The agreement is expected to accelerate Cipla’s global lung leadership agenda

To accomplish this, the parties will create a joint venture company with an aim to enter the respiratory biosimilars space.

By pooling resources, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of biopharmceutical products.

The companies expect Cipla’s respiratory expertise combined with Kemwell’s capabilities in biologics will accelerate bringing cost-effective biopharmaceutical products to market.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said the agreement is in line with its aspiration to become a global lung leader.